Zika virus (ZIVK) represents a new threat to global health, with particular relevance to neuroscientists, due to associated newborn and adult neurological disease. Consequences of vertical infection include microcephaly with brain and eye anomalies, and consequences of adult infection include Guillain-Barré syndrome (GBS) and meningoencephalitis. Recent data suggest specific vulnerability of neural progenitors to infection, leading to cell death and brain calcification, reminiscent of other viral syndromes. Prevailing models suggest entry into neuronal stem cells through transmembrane receptors, hijacking cellular signaling to interfere with neurogenesis and cell survival. Mechanisms of adult neurological disease are unknown, but recent evidence suggests propensity for infection of adult neural stem cells. Efforts focused on mechanisms of pathogenesis, vulnerabilities, and treatments are urgently needed.
Introduction
A couple of years ago, an encounter with a mosquito did not pose a major health concern to most of the developed world. Unfortunately, with the dire effects of Zika virus (ZIKV) on fetal brain development seen in Brazil and the spread of ZIKV with Aedes mosquito and human transmission, ZIKV is now a serious threat with the potential to impact generations and societies worldwide. Neurobiologists and virologists have answered the urgent call to understand the underlying biology of ZIKV infection and have made remarkable progress in uncovering some important facts about ZIKV and its neurological impact. In this Review, we discuss ZIKV from a neurobiology perspective through evaluation of clinical, mechanistic, and historical information. We discuss the current status of the pandemic, the species-specific interferon responses, microcephaly, acute flaccid paralysis (AFP), and meningoencephalitis. We consider why ZIKV is just emerging as a neuro-pathogen now and how ZIKV can lead to death of neurons and clinical outcomes and compare ZIKV with relevant neuropathic viruses.
Overview of ZIKV Pandemic ZIKV was initially isolated from a sentinel rhesus monkey in the Zika forest of Uganda in 1947 (Dick et al., 1952 . In the same forest, ZIKV was isolated from Aedes africanus mosquitoes in 1948. As early as 1952, inoculation of mice with isolated virus demonstrated neural tropism, showing neuronal degeneration, cellular infiltration, and areas of softening in infected mouse brains (Dick, 1952 ). Yet, no evidence for human neurological disease emerged for over 50 years. Although a human infection was documented in 1954 (MacNamara, 1954) , only 14 human cases were reported before April 2007. The first ZIKV outbreak occurred on Yap Island in the western Pacific Ocean, during which 73% of the residents on the island were infected (Duffy et al., 2009) . In 2013, an outbreak of ZIKV occurred in French Polynesia, co-occurring with a dramatic 40-fold increase in the number of cases of Guillain-Barré syndrome (GBS) (Cao-Lormeau et al., 2016). In late 2014, the first confirmed cases were reported in northeastern Brazil. The reports from Brazil associated ZIKV with an increase incidence in fetal microcephaly, as well as in Guillain-Barré syndrome (Figure 1 ). Over the past year, ZIKV has spread widely in South and Central America, the Caribbean, and now into North America. As of August 2016, over 52 countries and territories have reported cases with active ZIKV transmission (http://www.cdc.gov/zika/geo/ index.html). In the United States, thousands of travel-associated cases have been reported, together with newly documented, locally acquired, mosquito-borne cases in southern US regions.
Virology of ZIKV and Immune Response
ZIKV is a positive, single-strand-enveloped RNA virus that belongs to the Flavivirus genus of the Flaviviridae family that includes several human pathogens, such as yellow fever (YFV), dengue (DENV), Japanese encephalitis (JEV), tick-borne encephalitis (TBEV), and West Nile (WNV) viruses. ZIKV genome includes two noncoding regions and one region encoding a polyprotein that is cleaved into ten proteins, including capsid, membrane precursor, and envelope, and seven nonstructural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5) (Figure 2A) .
Like other flaviviruses, ZIKV likely gains entry into host cells through endocytosis initiated upon interaction of the virus envelope glycoprotein with cell surface receptors. Several entry factors have been reported to facilitate viral entry of flavivirus, including the TAM family of receptor tyrosine kinases (TYRO3, AXL, and MER), T cell immunoglobulin and mucin domain (TIM) proteins, C-type lectin receptors, and the phosphatidylserine receptors (Perera-Lecoin et al., 2013) . Among these is the candidate AXL, based upon its role in mediating entry of DENV (Meertens et al., 2012) (Figure 2B ). In the case of DENV, association of the virus with the receptor activates the kinase activity of AXL, which in turn recruits interferon receptor (IFNAR), inhibiting innate antiviral response and facilitating viral replication (Rothlin et al., 2007) . Importantly, blocking AXL function with neutralizing
